AMAG's Feraheme non-inferior to iron sucrose in anemia trial

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) said IV Feraheme was non-inferior to IV iron sucrose on the co-primary endpoints in a Phase III trial to treat iron deficiency anemia. The endpoints were mean change from baseline in hemoglobin at week five and the proportion of patients who achieve at least a 2 g/dL increase in hemoglobin at any time from baseline to week five. The open-label, international trial enrolled 605 patients with a history of unsatisfactory oral iron therapy and who had iron deficiency anemia associated with various conditions, including abnormal uterine bleeding, cancer and gastrointestinal disorders. AMAG, which made the announcement after market close, was off $1.06 to $14.98 on Wednesday. ...